Rituximab in relapsing‐remitting multiple sclerosis: a 72‐week, open‐label, phase I trial

A Bar‐Or, PAJ Calabresi, D Arnold… - Annals of …, 2008 - Wiley Online Library
We evaluated the safety, tolerability, pharmacodynamics, and activity of B‐cell depletion with
rituximab in patients with relapsing‐remitting multiple sclerosis, receiving two courses of …
被引用次数：603 相关文章

[引用][C] Rituximab in Relapsing-Remitting Multiple Sclerosis: A 72-Week, Open-Label, Phase I Trial

A BAR-OR, PAJ CALABRESI, N SARKAR… - Annals of …, 2008 - pascal-francis.inist.fr
Rituximab in Relapsing-Remitting Multiple Sclerosis : A 72-Week, Open-Label, Phase I Trial
CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple …

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.

A Bar-Or, PA Calabresi, D Arnold, C Markowitz… - Annals of …, 2008 - europepmc.org
We evaluated the safety, tolerability, pharmacodynamics, and activity of B-cell depletion with
rituximab in patients with relapsing-remitting multiple sclerosis, receiving two courses of …

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

A Bar-Or, PAJ Calabresi, D Arnold… - Annals of …, 2008 - pubmed.ncbi.nlm.nih.gov
We evaluated the safety, tolerability, pharmacodynamics, and activity of B-cell depletion with
rituximab in patients with relapsing-remitting multiple sclerosis, receiving two courses of …

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

A Bar-Or, PAJ Calabresi, D Arnlod… - Annals of …, 2008 - pure.johnshopkins.edu
We evaluated the safety, tolerability, pharmacodynamics, and activity of B-cell depletion with
rituximab in patients with relapsing-remitting multiple sclerosis, receiving two courses of …

[引用][C] Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

A Bar-Or, PAJ Calabresi, D Arnold, C Markowitz… - Annals of …, 2008 - cir.nii.ac.jp

[引用][C] Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label phase I trial

A BAR-OR - Ann Neurol, 2008 - cir.nii.ac.jp
Rituximab in relapsing-remitting multiple sclerosis : a 72-week, open-label phase I trial |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォーム …

[引用][C] Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase 1 trial (Annals of Neurology (2007)(399-495))

A Bar-Or, PAJ Calabresi, D Arnold… - Annals of …, 2008 - pure.johnshopkins.edu
Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase 1 trial (Annals
of Neurology (2007) (399-495)) — Johns Hopkins University Skip to main navigation Skip to …

[引用][C] Rituximab in Relapsing-Remitting Multiple Sclerosis: A 72-Week, Open-Label, Phase I Trial

A BAR-OR, PAJ CALABRESI, D ARNLOD… - Annals of …, 2008 - Wiley-Liss